August 08, 2018 - Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has filed a financial statement reporting Earnings Per Share Basic And Diluted of $-0 USD. Previously, on May 09, 2018, Ra Pharmaceuticals, Inc. reported Earnings Per Share Basic And Diluted of $-1 USD.
Related News Stories
Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M. (30-0)
Ra Pharma is developing RA101495, a C5 inhibitor and a potential competitor to Alexion's blockbuster Soliris. (7-0)
TNXP remains appropriate only for investors who can stomach the high risk in this potentially high-reward punt. (7-5)
Shares of Ra Pharmaceuticals (NASDAQ:RARX) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. (8-0)
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside. (55-17)